Advertisement
Australia markets close in 5 hours 25 minutes

  • ALL ORDS

    7,823.30
    -75.60 (-0.96%)
     

  • ASX 200

    7,567.60
    -74.50 (-0.97%)
     

  • AUD/USD

    0.6412
    -0.0014 (-0.21%)
     

  • OIL

    82.48
    -0.25 (-0.30%)
     

  • GOLD

    2,391.50
    -6.50 (-0.27%)
     

  • Bitcoin AUD

    98,364.73
    +2,845.60 (+2.98%)
     

  • CMC Crypto 200

    1,302.35
    +416.81 (+46.59%)
     

  • AUD/EUR

    0.6025
    -0.0006 (-0.10%)
     

  • AUD/NZD

    1.0871
    -0.0004 (-0.04%)
     

  • NZX 50

    11,793.25
    -42.79 (-0.36%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • NIKKEI 225

    37,364.17
    -715.53 (-1.88%)
     

Treace to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc.

PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com